Drugs / VK2735
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05203237 | Dec 2021 → Nov 2024 | metabolic dysfunction-associated steatohepatitis | Viking Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 2 met primary | ||||||
| Phase 2 | NCT06828055 | Dec 2024 → Jun 2025 | — | Viking Therapeutics, Inc. | Completed | Met primary |
| Phase 2 | NCT06068946 | Aug 2023 → Feb 2024 | — | Viking Therapeutics, Inc. | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT07104500 | Jun 2025 → Jul 2027 expected | — | Viking Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07104383 | Jun 2025 → Jul 2027 expected | — | Viking Therapeutics, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2026-05-12 | Viking Therapeutics, Inc. | Results Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 vikingtherapeutics.com ↗
Participants receiving once-daily oral VK2735 demonstrated statistically significant, dose-dependent weight loss from baseline of up to 12.2% (26.6 lbs) at 13 weeks across all dose cohorts. |
| 2026-01-12 | Viking Therapeutics, Inc. | Results Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity vikingtherapeutics.com ↗
After 13 weekly subcutaneous doses, participants receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7% with no signs of plateau. |
| 2025-11-06 | Viking Therapeutics, Inc. | Results Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025 vikingtherapeutics.com ↗
Treatment with VK2735 was shown to improve cardiometabolic parameters in patients, including reductions in the prevalence of prediabetes and MetS at the end of the 13-week treatment period. |
| 2025-08-19 | Viking Therapeutics, Inc. | Results Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity vikingtherapeutics.com ↗
The Phase 2 VENTURE-Oral Dosing trial successfully achieved its primary and secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo. |
| 2024-11-04 | Viking Therapeutics, Inc. | Results Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024 vikingtherapeutics.com ↗
Highlights from one poster presentation include new data from the company's Phase 1 multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735 dosed daily for 28 days, including results for the study's 60 mg, 80 mg, and 100 mg daily treatment cohorts. |
| 2024-03-26 | Viking Therapeutics, Inc. | Results Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 vikingtherapeutics.com ↗ |
| 2024-02-27 | Viking Therapeutics, Inc. | Results Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity vikingtherapeutics.com ↗
The Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo. |
| 2023-10-17 | Viking Therapeutics, Inc. | Results Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023 vikingtherapeutics.com ↗
Highlights from the oral presentation include newly reported data demonstrating that 28 days of once-weekly treatment with VK2735 resulted in reductions in subjects' liver fat content and plasma lipid levels, both from baseline and as compared to placebo. |
| 2023-03-28 | Viking Therapeutics, Inc. | Results Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 vikingtherapeutics.com ↗
Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive results from the company's Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735. |
| 2021-11-01 | Viking Therapeutics, Inc. | Results Viking Therapeutics Presents Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek® 2021 vikingtherapeutics.com ↗
The results of the studies demonstrate that addition of GIP receptor activity improves upon the observed effects resulting from activation of the GLP-1 receptor alone in DIO mouse models. |
All press releases naming this drug 26 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VK2735 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07104383 ↗ |
| Action | Activate | “VK2735, a Dual Glucagon-like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonist” NCT05203237 ↗ |
| Modality | Peptide | “VK2735 is a peptide GLP-1 and GIP dual agonist” NCT06068946 ↗ |
| Route | Subcutaneous | “Administered SC” NCT05203237 ↗ |